HOXA5 and lung adenocarcinoma: Immunohistochemistry assays for p53 and HOXA5 conducted on primary NSCLC samples revealed that patients exhibiting no immune response to either p53 or HOXA5 experienced unfavorable outcomes.[37] Notably, the overexpression of HOXA5 in lung adenocarcinoma cells demonstrated a restraining effect on proliferation, invasion, and filopodia proliferation, along with the inhibition of in vivo metastasis.